Celldex Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. is a U.S.-listed biotechnology company trading on the NASDAQ under the ticker CLDX, and its headquarters are in Hampton, New Jersey, United States. For French-speaking investors in France, Belgium, and Switzerland, Celldex should be viewed as a specialized immunology biotech rather than a diversified pharmaceutical company. Its investment case is driven primarily by clinical development execution, trial readouts, and the company’s ability to fund late-stage programs, rather than by current commercial sales. ([ir.celldex.com](https://ir.celldex.com/investor-relations?utm_source=openai)) Founded in 1991, Celldex has gradually transformed from a broader biotech platform into a more focused company centered on immunology and antibody-based therapies. Management describes the strategy as aiming to realign the immune response, with a focus on allergic, inflammatory, and autoimmune disorders. That strategic narrowing improves thematic clarity, but it also means the company remains highly dependent on a limited number of clinical assets. In equity terms, Celldex is still a development-stage biotechnology name with elevated binary risk and meaningful upside if its lead programs continue to perform. ([ir.celldex.com](https://ir.celldex.com/investor-relations?utm_source=openai)) The key value driver is barzolvolimab, a KIT-targeting antibody designed to affect mast cells, which are central to several urticaria and allergic disease pathways. Recent company disclosures indicate encouraging Phase 2 data in chronic spontaneous urticaria, cold urticaria, and symptomatic dermographism. In May 2026, Celldex reported that enrollment in both Phase 3 chronic spontaneous urticaria studies, EMBARQ-CSU 1 and 2, had been completed six months ahead of guidance, with top-line data expected in Q4 2026 and a BLA submission planned for 2027. The pipeline also includes CDX-622, which is being evaluated in a Phase 1 proof-of-mechanism study in asthma. ([ir.celldex.com](https://ir.celldex.com/news-releases/news-release-details/celldex-presents-data-demonstrating-barzolvolimab-improves?utm_source=openai)) From a competitive standpoint, Celldex operates in a crowded immunology and allergy market populated by large-cap pharmaceutical companies and specialty biotech peers. Its differentiation lies in mechanism innovation and the possibility of demonstrating first-in-class or best-in-disease efficacy in symptomatic, high-burden indications. The flip side is that Celldex does not yet have a broad commercial portfolio, so valuation is likely to remain highly sensitive to clinical milestones, safety data, and financing decisions. ([ir.celldex.com](https://ir.celldex.com/investor-relations?utm_source=openai)) Geographically, the company’s footprint is almost entirely U.S.-based, with locations in New Jersey, Connecticut, and Massachusetts. Its operations are concentrated on research, development, and scientific collaboration, with no major international commercial footprint disclosed in the recent materials reviewed. Recent headline events include a $345 million gross follow-on equity offering closed in April 2026 and multiple conference presentations highlighting barzolvolimab data in 2025 and 2026. For investors, Celldex remains a classic NASDAQ-listed U.S. biotech story: scientifically promising, clinically driven, and inherently dependent on execution over the next several quarters. ([ir.celldex.com](https://ir.celldex.com/investor-relations?utm_source=openai))